NP5.F NEWRON PHARMACEUT. EO-20

Healthcare Biotechnology Frankfurt Exchange
9.54 EUR
Close of Nov 12, 2026
6.50 33.55
Market cap
EUR 195M
P/E
-
P/B
172.36x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is NP5.F undervalued?

Graham number

The Graham number of NEWRON PHARMACEUT. EO-20 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NEWRON PHARMACEUT. EO-20 fundamental analysis

No fundamental analysis for NEWRON PHARMACEUT. EO-20 yet.

NEWRON PHARMACEUT. EO-20 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NEWRON PHARMACEUT. EO-20

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizo…

Full company profile